Almost exactly a year after Dendreon Corp. set the prostate cancer space abuzz with the approval of immunotherapy Provenge (sipuleucel-T), Centocor Ortho Biotech Inc. scored another win with an FDA nod for abiraterone, an oral androgen biosynthesis inhibitor, roughly two months ahead of schedule.